The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Real world safety and efficacy of belumosudil: Results from the ROCKreal trial
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
The ROCKreal trial investigated the safety and efficacy of belumosudil in patients with cGvHD. How did the 6-month overall response rate compare between patients who received belumosudil and those who received best-available therapy (BAT)?
A
B
C
⭐GvHD Hub spotlight: The ROCKreal study ⭐
At 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Edmund Waller, Emory Winship Cancer Institute, Atlanta, US, discussed results from the ROCKreal trial investigating the real-world safety and efficacy of belumosudil for cGvHD vs best available therapy.
Waller EK. Efficacy and safety of belumosudil as compared with best available therapy for the treatment of chronic graft versus host disease in the US population. Oral Abstract #OS11-03. 51st Annual Meeting of the EBMT; Mar 30 – Apr 2, 2025; Florence, IT.
This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
